A 52-year-old woman with a 15-year history of hypertension presents with progressive fatigue and nocturia ×3 per night. On examination, blood pressure is 162/98 mmHg, and there is mild bilateral ankle edema. Laboratory findings: serum creatinine 1.9 mg/dL, eGFR 38 mL/min/1.73 m², serum potassium 5.2 mEq/L, serum phosphate 3.8 mg/dL, hemoglobin 10.1 g/dL, and urinalysis shows 1+ proteinuria. Renal ultrasound demonstrates normal-sized kidneys with increased echogenicity. Which of the following complications is she at highest risk of developing in the next 1–2 years if current management is suboptimal?

Explanation

## Clinical Context This patient has **Stage 3b CKD** (eGFR 30–44 mL/min/1.73 m²) secondary to **hypertensive nephrosclerosis**, evidenced by: - Long-standing hypertension (15 years) - Normal-sized kidneys with increased echogenicity (fibrosis) - Mild proteinuria (1+) - Mild anemia (Hb 10.1 g/dL) - Hypertension inadequately controlled (162/98 mmHg) ## Pathophysiology of Hypertensive CKD **Key Point:** Chronic hypertension causes: 1. **Glomerular capillary hypertension** → proteinuria and glomerulosclerosis 2. **Arterial stiffening** → left ventricular hypertrophy (LVH) and diastolic dysfunction 3. **Tubulointerstitial fibrosis** → progressive eGFR decline 4. **Increased afterload** → cardiac remodeling and eventual systolic dysfunction ## Cardiovascular Consequences in CKD | Complication | Mechanism | Timeline | Prevention | |---|---|---|---| | **LVH & diastolic dysfunction** | Chronic hypertension + anemia + fluid retention | 1–2 years | ACE-I/ARB, BP control <130/80 mmHg | | **Systolic heart failure** | Progressive LVH → eccentric remodeling | 3–5 years | Optimal medical therapy | | **Arrhythmias** | LVH, hyperkalemia, electrolyte disturbances | Variable | Electrolyte management | | **Sudden cardiac death** | LVH, ischemia, arrhythmias | Variable | Risk factor modification | **High-Yield:** Patients with CKD and hypertension have a **5–10-fold higher risk of cardiovascular death** than the general population. LVH is present in ~70% of CKD Stage 3–4 patients and is an independent predictor of mortality. ## Why This Answer Is Correct Given her: - Uncontrolled hypertension (162/98 mmHg) - Anemia (Hb 10.1 g/dL) — increases cardiac workload - Stage 3b CKD with proteinuria - Nocturia and ankle edema — signs of fluid retention and cardiac stress **LVH with diastolic dysfunction is the most likely and most common complication** to develop over 1–2 years if blood pressure and anemia are not aggressively managed. This is a direct consequence of chronic hypertension in the setting of reduced renal function. ## Clinical Pearl **Echocardiography is recommended in all CKD Stage 3–4 patients with hypertension** to assess for LVH and diastolic dysfunction. Early detection allows for intensified antihypertensive therapy and ACE-I/ARB use to regress LVH. ## Management to Prevent This Complication 1. **Target BP <130/80 mmHg** (KDIGO 2021) — more aggressive than general population 2. **ACE-I or ARB** — first-line agents; reduce LVH and proteinuria 3. **Anemia correction** — target Hb 10–12 g/dL with ESA if indicated 4. **Sodium restriction** — <2 g/day 5. **Regular monitoring** — ECG, echocardiography as clinically indicated